Next Article in Journal
Microenvironments and Cellular Characteristics in the Micro Tumor Cords of Malignant Solid Tumors
Next Article in Special Issue
Profound Re-Organization of Cell Surface Proteome in Equine Retinal Pigment Epithelial Cells in Response to In Vitro Culturing
Previous Article in Journal
Injurious Effects of Emodin on Maturation of Mouse Oocytes, Fertilization and Fetal Development via Apoptosis
Previous Article in Special Issue
Profiling the Proteome of Exhaled Breath Condensate in Healthy Smokers and COPD Patients by LC-MS/MS
Int. J. Mol. Sci. 2012, 13(11), 13926-13948; doi:10.3390/ijms131113926
Review

The Proteomics Big Challenge for Biomarkers and New Drug-Targets Discovery

,
,
 and *
Received: 24 September 2012; in revised form: 17 October 2012 / Accepted: 25 October 2012 / Published: 29 October 2012
(This article belongs to the collection Advances in Proteomic Research)
View Full-Text   |   Download PDF [877 KB, uploaded 19 June 2014]   |   Browse Figures
Abstract: In the modern process of drug discovery, clinical, functional and chemical proteomics can converge and integrate synergies. Functional proteomics explores and elucidates the components of pathways and their interactions which, when deregulated, lead to a disease condition. This knowledge allows the design of strategies to target multiple pathways with combinations of pathway-specific drugs, which might increase chances of success and reduce the occurrence of drug resistance. Chemical proteomics, by analyzing the drug interactome, strongly contributes to accelerate the process of new druggable targets discovery. In the research area of clinical proteomics, proteome and peptidome mass spectrometry-profiling of human bodily fluid (plasma, serum, urine and so on), as well as of tissue and of cells, represents a promising tool for novel biomarker and eventually new druggable targets discovery. In the present review we provide a survey of current strategies of functional, chemical and clinical proteomics. Major issues will be presented for proteomic technologies used for the discovery of biomarkers for early disease diagnosis and identification of new drug targets.
Keywords: biomarkers; mass spectrometry; MALDI-TOF; proteomics; bodily fluids; tissues biomarkers; mass spectrometry; MALDI-TOF; proteomics; bodily fluids; tissues
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Savino, R.; Paduano, S.; Preianò, M.; Terracciano, R. The Proteomics Big Challenge for Biomarkers and New Drug-Targets Discovery. Int. J. Mol. Sci. 2012, 13, 13926-13948.

AMA Style

Savino R, Paduano S, Preianò M, Terracciano R. The Proteomics Big Challenge for Biomarkers and New Drug-Targets Discovery. International Journal of Molecular Sciences. 2012; 13(11):13926-13948.

Chicago/Turabian Style

Savino, Rocco; Paduano, Sergio; Preianò, Mariaimmacolata; Terracciano, Rosa. 2012. "The Proteomics Big Challenge for Biomarkers and New Drug-Targets Discovery." Int. J. Mol. Sci. 13, no. 11: 13926-13948.


Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert